Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Results from a phase 1 trial have supported further clinical evaluation with a dose-dependent WL up to 14.5% with AMG133 compared to 1.5% with placebo by day 85 [59]
However, nearly all data come from lab and animal studies rather than controlled human trials, so claims about systemic hormone changes warrant caution
For comparison, a B12 tablet leaves you with only 1.2% of B12 in the tablet
BPC-157 Route Selection Oral BPC-157 (250 to 500 mcg, 1 to 2 times daily on an empty stomach): Best for patients whose primary goal is GI support during GLP-1 therapy
Cautions: If pregnant, nursing, or under medical supervision, consult your healthcare practitioner before use
Prospective studies should incorporate clinically meaningful endpoints rather than surrogate mechanistic outcomes
